Sera Prognostics (SERA) Preferred Stock Liabilities (2020 - 2021)
Sera Prognostics (SERA) reported Preferred Stock Liabilities of $77.8 million for Q2 2021, little changed on a YoY basis from $77.8 million in Q2 2020, and down 29.55% quarter-over-quarter from $110.5 million in Q1 2021.
Sera Prognostics (SERA) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends
Sera Prognostics has reported Preferred Stock Liabilities for 2 years, with the latest figure at $77.8 million in Q2 2021.
- For the quarter ending Q2 2021, Preferred Stock Liabilities changed 0.0% year-over-year to $77.8 million; the trailing twelve-month figure through Jun 2021 stood at $77.8 million (changed 0.0% YoY), and the FY2020 full-year result was $474000.0, changed N/A from the prior year.
- Preferred Stock Liabilities for Q2 2021 stood at $77.8 million, down from $110.5 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $110.5 million in Q1 2021, with the low at $474000.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | - |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | - |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | - |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | - |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | - |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | - |
| 10 | Sera Prognostics | 93.48 Mn | 93.48 Mn | -28,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 77.84 Mn |
| Mar 31, 2021 | 110.50 Mn |
| Dec 31, 2020 | 474,000.00 |
| Sep 30, 2020 | 50.19 Mn |
| Jun 30, 2020 | 77.84 Mn |